Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515730 | 1.00 | MAPT (0.47) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL518051 | 0.88 | LMNA (0.43) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23654672 | 0.87 | ALDH1A1 (0.45) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL517279 | 0.82 | ALDH1A1 (0.64) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL517280 | 0.82 | ALDH1A1 (0.64) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL517549 | 0.81 | HTR4 (0.42) | MAPTKMT2AALDH1A1 | |
| SCHEMBL517901 | 0.80 | ALDH1A1 (0.45) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31458455 | 0.80 | ALDH1A1 (0.45) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15103634 | 0.80 | MAPT (0.60) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15103633 | 0.80 | MAPT (0.60) | MAPTLMNAKMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | MAPT 2815/4885LMNA 1889/4885KMT2A 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.